PPIG and metabolic dysfunction-associated steatohepatitis: Therapeutic indication: cholestatic disorders, non-alcoholic steatohepatitis (NASH)Target: bile acid nuclear receptor (novel drug target)Residual uncertainty• Limited information on target pharmacology• Increased liver weight in multiple species, capacity to induce CYP and bile acid transporter in vitro• Lack of 6-month rat toxicology study• Limited assessment on potential hormonal effects• Lack of precedent for compounds of this drug class